Mission links with AbbVie to develop Alzheimer’s, Parkinson’s therapies
UK drug discovery and development group Mission Therapeutics has signed a deal with AbbVie focusing on early stage development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease.
Read More
